1321600-78-5

Basic information

• Product Name: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]-N-acetyl]amino]phenyl]benzamide
• Synonyms: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]-N-acetyl]amino]phenyl]benzamide
• CAS NO: 1321600-78-5
• Molecular Weight: 535.649
• Mol File: 1321600-78-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]-N-acetyl]amino]phenyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]-N-acetyl]amino]phenyl]benzamide(1321600-78-5)
• EPA Substance Registry System: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]-N-acetyl]amino]phenyl]benzamide(1321600-78-5)

Safety Data

• Hazardous Substances Data: 1321600-78-5(Hazardous Substances Data)

Upstream product

• 1642-81-5 p-(chloromethyl)benzoic acid 
• 404844-11-7 4-(chloromethyl)-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]-amino}phenyl)benzamide 
• 152460-10-1 6-methyl-1-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 108-24-7 acetic anhydride 
• 152459-95-5 imatinib 

Relevant articles and documents

HIGHLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided herein are impurities of imatinib, N-acetylpiperazine, N-acetylamino, N- chloromethylamino, formamide, 4-methylbenzamide and '2.24 RRt' impurities, and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of at least one, or two, or more, of the N-acetylpiperazine, N-acetylamino, N-chloromethylamino, formamide, 4-methylbenzamide, and '2.24 RRt' impurities, processes for the preparation, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure α-form of imatinib mesylate.